Clinical Trial Update: Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating axitinib, an anti-angiogenesis agent, in patients with stage III malignant melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Melanoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: University of California, Irvine | Conditions: Melanoma, Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-01-20